Samsung Biologics stock: 20% sales growth target after Q3 beat

Published on 11/02/2026 at 01:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Samsung Biologics stock enters the final quarter after stronger-than-expected operating results. Labor talks and expansion spending remain key investor issues.

Growth outlook meets execution challenges

Third-quarter sales rose on stronger manufacturing activity and new U.S. operations.
Operating profit growth lagged sales growth, while the operating margin declined from a year earlier.
A court ruling limited disruption risks as labor negotiations were set to resume in November.

Samsung Biologics, KR7207940008, Illustration mit AI erstellt.

Samsung Biologics lifted its full-year sales-growth outlook after preliminary third-quarter results exceeded brokerage forecasts. The update, reported by The Herald Business on October 22, 2026, puts execution and labor relations at the center of the investment case.

Revenue growth raises the target

Samsung Biologics reported third-quarter sales of KRW 1.49 trillion, up 18.5 percent from a year earlier. Operating profit reached KRW 640.1 billion, an increase of 1.0 percent, while net profit fell 21.2 percent to KRW 391.1 billion.

The operating margin was 43.0 percent, down from 50.4 percent a year earlier and 44.4 percent in the previous quarter. The combination of strong sales and slower profit growth points to pressure from ramp-up costs, production disruption and the integration of new capacity.

The company raised its full-year sales target from KRW 5.32 trillion to KRW 5.47 trillion. The Herald Business said more than KRW 4 trillion had already been generated through the first three quarters, leaving roughly KRW 1.4 trillion to reach the revised goal in the final quarter.

Labor risk remains in focus

A Seoul High Court ruling recognized nine production processes as essential security work that should continue during a strike. The union subsequently postponed a planned second general strike, while management and labor scheduled further negotiations for November.

The company is also pursuing the acquisition of PolyPeptide Group after securing an 87.88 percent tender result, according to The Herald Business. The transaction would broaden Samsung Biologics' contract development and manufacturing offering into peptide-based therapeutics, subject to remaining regulatory steps.

Global CDMO expansion continues

Samsung Biologics operates as a contract manufacturing and contract development organization for biopharmaceutical customers. Its activities span manufacturing capacity in South Korea and the United States, while its commercial network covers the United States, Europe, Japan and Asia-Pacific. The company is expanding beyond antibody-focused services through the planned PolyPeptide transaction and is positioning its global production footprint for large international drugmakers.

The company's investor relations page lists third-quarter 2026 reporting and recent PolyPeptide tender-offer notices.

The KOSPI provides the relevant South Korean market backdrop for Samsung Biologics stock.

More news and analyses on Samsung Biologics stock.